Trader consensus strongly favors "No" at 93% implied probability for a new coronavirus pandemic in 2026, driven by the absence of any confirmed novel coronavirus—distinct from SARS-CoV-2—emerging with sustained human-to-human transmission, per ongoing WHO and CDC surveillance. COVID-19 variants like BA.3.2 and Nimbus continue circulating at low endemic levels, with CDC data as of May 5 showing infections declining or likely declining in 26 U.S. states and stable globally via reduced case reports and testing volumes. Population immunity from prior SARS-CoV-2 exposures provides cross-protection against related coronaviruses, lowering spillover risks as evidenced by recent epidemiological analyses. Realistic challenges include an unforeseen zoonotic event, such as rapid adaptation of animal coronaviruses like HKU5-CoV-2, prompting WHO pandemic declaration; watch for weekly WHO dashboards and genomic surveillance updates.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoNova pandemia de coronavírus em 2026?
Nova pandemia de coronavírus em 2026?
Sim
$13,451 Vol.
$13,451 Vol.
Sim
$13,451 Vol.
$13,451 Vol.
The resolution source will be official announcements from the World Health Organization.
Mercado Aberto: Jan 6, 2026, 2:40 PM ET
Resolver
0x65070BE91...The resolution source will be official announcements from the World Health Organization.
Resolver
0x65070BE91...Trader consensus strongly favors "No" at 93% implied probability for a new coronavirus pandemic in 2026, driven by the absence of any confirmed novel coronavirus—distinct from SARS-CoV-2—emerging with sustained human-to-human transmission, per ongoing WHO and CDC surveillance. COVID-19 variants like BA.3.2 and Nimbus continue circulating at low endemic levels, with CDC data as of May 5 showing infections declining or likely declining in 26 U.S. states and stable globally via reduced case reports and testing volumes. Population immunity from prior SARS-CoV-2 exposures provides cross-protection against related coronaviruses, lowering spillover risks as evidenced by recent epidemiological analyses. Realistic challenges include an unforeseen zoonotic event, such as rapid adaptation of animal coronaviruses like HKU5-CoV-2, prompting WHO pandemic declaration; watch for weekly WHO dashboards and genomic surveillance updates.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions